Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

10.0%

1 terminated out of 10 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

9Total
Not Applicable (1)
P 1 (6)
P 2 (2)

Trial Status

Recruiting4
Unknown3
Active Not Recruiting1
Terminated1
Withdrawn1

Clinical Trials (10)

Showing 10 of 10 trials
NCT07075185Phase 1Recruiting

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

NCT06644625Recruiting

CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study

NCT06485076Not ApplicableRecruiting

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

NCT07032129Phase 1Recruiting

Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma

NCT06411301Phase 1Withdrawn

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors

NCT03428373Phase 2Active Not Recruiting

Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma

NCT03687125Phase 1Terminated

Tinostamustine Conditioning and Autologous Stem Cell

NCT03672253Phase 1Unknown

CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma

NCT03601624Phase 2Unknown

Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans

NCT03706547Phase 1Unknown

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Showing all 10 trials

Research Network

Activity Timeline